Personal information

Emails & domains

Verified email addresses

Verified email domains

Other IDs

SciProfiles: 2821850

Keywords

chronic lymphocytic leukemia, next generation sequencing, molecular genetics, oncology, haematology

Countries

Hungary

Activities

Collapse all

Employment (1)

Semmelweis University: Budapest, HU

PhD student (Pathology and Experimental Cancer Research, HCEMM-SU Molecular Oncohematology Research Group)
Employment
Source: Self-asserted source
Tamás László

Education and qualifications (1)

University of Medicine and Pharmacy of Târgu Mureş: Târgu Mureş, RO

2015 to 2021 | General medicine
Education
Source: Self-asserted source
Tamás László

Professional activities (3)

European Hematology Association: The Hague, NL

2022 to present | Junior member
Membership
Source: Self-asserted source
Tamás László

Raoul Wallenberg Institute: Budapest, HU

2022 to 2023 | Invited teacher
Invited position
Source: Self-asserted source
Tamás László

Junior Researcher Academy, University of Medicine and Pharmacy, Targu Mures: Targu Mures, RO

2020 to 2021 | Entry level member
Membership
Source: Self-asserted source
Tamás László

Works (7)

Konferenciabeszámoló: ERIC PRECEPTORSHIP (Realizing precision medicine in CLL: Why and how)

Hematológia–Transzfuziológia
2024-06-03 | Journal article
DOI: 10.1556/2068.2024.10007
Contributors: Tamás László
Source: check_circle
Crossref

Low‐burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation

The Journal of Pathology: Clinical Research
2024-01 | Journal article
DOI: 10.1002/cjp2.351
Contributors: Tamás László; Lili Kotmayer; Viktória Fésüs; Lajos Hegyi; Stefánia Gróf; Ákos Nagy; Béla Kajtár; Alexandra Balogh; Júlia Weisinger; Tamás Masszi et al.
Source: check_circle
Crossref

Az immunglobulin-nehézláncgén variábilis régió (IGHV) mutációs státuszának meghatározása új generációs szekvenálással krónikus limfocitás leukémiában

Hematológia–Transzfuziológia
2023-12-15 | Journal article
DOI: 10.1556/2068.2023.00183
Contributors: Tamás László; Erik Zajta; Róbert Horváth; Lili Kotmayer; Lajos Hegyi; Csaba Bödör
Source: check_circle
Crossref

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

International Journal of Molecular Sciences
2023-03-18 | Journal article
DOI: 10.3390/ijms24065802
Contributors: Lili Kotmayer; Tamás László; Gábor Mikala; Richárd Kiss; Luca Lévay; Lajos László Hegyi; Stefánia Gróf; Tibor Nagy; Gábor Barna; Péter Farkas et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Beszámoló az ERIC CLL 2022 Kongresszusról

Hematológia–Transzfuziológia
2022-12-21 | Journal article
DOI: 10.1556/2068.2022.30007
Contributors: Tamás László
Source: check_circle
Crossref

Venetoclax-rezisztencia krónikus lymphocytás leukémiában

Hematológia–Transzfuziológia
2021-12-07 | Journal article
DOI: 10.1556/2068.2021.54.3.4
Part of ISSN: 1786-5913
Part of ISSN: 0324-7309
Source: Self-asserted source
Tamás László

Screening and monitoring of the BTK C481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy

British Journal of Haematology
2021-07 | Journal article
DOI: 10.1111/bjh.17502
Part of ISSN: 0007-1048
Part of ISSN: 1365-2141
Source: Self-asserted source
Tamás László
How many people are using ORCID?